Speaker Biography

Genc Struga

University Hospital Mother Tereza

Title: Using alternative medicine Nuraid II in the treatment of acute phase of stroke

Genc Struga

Genc Struga is a Consultant Neurologist and Stroke in University Hospital Mother Tereza and attending Physician at Cerebrovascular Intensive Care Unit. He is an Experienced Consultant with a demonstrated history of working in the hospital & health care industry. Skilled in Clinical Research, Medical Education, Medicine, Neurology&Stroke, Neurosonology and Clinical Trials. Strong consulting professional with a Doctor of Philosophy (Ph.D.) focused in Neuroscience from University of Tirana Faculty of Medicine.


NurAiD II contains 9 natural herbal extracts with proven effect to stimulate neuroplasticity and improve morbidity and cognition particularly in patients with ischemic stroke. The effect is in proliferation, differentiation and the migration of neuronal cells and the formation of new neuronal circuits affecting recovery of patients after stroke.

The activation by NeuroAid of the ATP-sensitive potassium channel located in the suffering neurons of the brain protects them from death. Indeed, the opening of the channel decreases the excitability of neurons (by hyperpolarization) preventing an overload of calcium and release of excitotoxic glutamate. Besides the beneficial effects in neuroplasticity already published, these results strengthen the interest of NeuroAid in stroke recovery.

NurAid II prevents necrosis and apoptotic cell death induced by global ischemia, enhances neurogenesis, and enhances functional recovery. This makes MLC901a potential novel therapeutic strategy in treating cognitive and neurological deficits caused by global ischemia from conditions that deprive the brain of oxygen and glucose, such as cardiac arrest.

Data from the Chinese MedicineNeuroaid Efficacy on Stroke recovery (CHIMES) study, an international, randomized, placebo-controlled, double-blind trial investigating the efficacy of MLC601 on stroke recovery in patients with ischemic stroke of intermediate severity in the preceding 72 hours showed improve long term morbidity and cognition. Functional independence defined as mRS ≤ 1 was significantly increased at 6 months and persisted up to 18 months after a stroke.

The results of the studies confirmed the overall benefit of NeuroAiD in stroke recovery and showed that treatment effect for achieving functional independence was greater among non-acute strokes, consistent with previous studies. In addition, the study showed that NeuroAiD had an excellent safety profile.